Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany

Inflammatory Bowel Diseases

Volumn 16, Issue 1, 2010, Pages 42-51

  Stark, Renee G ^a   Reitmeir, Peter ^a   Leidl, Reiner ^a,b   König, Hans Helmut ^c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

EQ 5D; Health related quality of life; Inflammatory bowel disease

Indexed keywords

ADULT; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; CROHN DISEASE; DETERIORATION; DISEASE ACTIVITY; EUROQOL 5D; FEMALE; GERMANY; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; REMISSION; SCORING SYSTEM; TEST RETEST RELIABILITY; ULCERATIVE COLITIS; UNITED KINGDOM; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GERMANY; GREAT BRITAIN; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; YOUNG ADULT;

EID: 74049094313     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20989     Document Type: Article

References (37)

1. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199-208.
2. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
3. Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ. 1996;5:141-154.
4. Dolan P, Roberts J. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care. 2002;40:442-446.
5. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-220.
6. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217-230.
7. Buxton MJ, Lacey LA, Feagan BG, et al. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility. Value Health. 2007;10:214-220.
8. Gunther OH, Roick C, Angermeyer MC, et al. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2008;105:81-91.
9. Moock J, Kohlmann T. Comparing preference-based quality-of-life measures: results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders. Qual Life Res. 2008;17:485-495.
10. Lamers LM, Stalmeier PF, McDonnell J, et al. [Measuring the quality of life in cost-utility analyses: the Dutch EQ-5D tariff.]Ned Tijdschr Geneeskd. 2005;149:1574-1578.
11. Greiner W, Claes C, Busschbach JJV, et al. Validating the EQ-5D with Time Trade Off for the German Population. Eur J Health Econ. 2005;62:124-130.
12. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36:551-559.
13. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart. 2006;92:62-67.
14. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004;13:1247-1253.
15. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444-454.
16. Drossman DA. Inflammatory bowel disease. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edition. Philadelphia: Lippincott-Raven;1996:925-935.
17. Martins NB, Peppercorn MA. Inflammatory bowel disease. Am J Manag Care. 2004;10:544-552.
18. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
19. Feagan BG. Economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther. 1999;13:29-37.
20. Bernstein CN, Walker JR, Graff LA. On studying the connection between stress and IBD. Am J Gastroenterol. 2006;101:782-785.
21. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4:1491-1501.
22. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54:1481-1491.
23. Rogala L, Miller N, Graff LA, et al. Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:526-535.
24. Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1575-1584.
25. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70.
26. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-383.
27. Konig HH, Ulshofer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1205-1215.
28. Petrak F, Hardt J, Clement T, et al. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol. 2001;36:375-382.
29. Best WR BJ, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
30. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
31. Janke KH, Raible A, Bauer M, et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis. 2004;19:343-353.
32. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
33. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991;12:142S-158S.
34. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37:360-363.
35. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24:797-814.
36. Middel B, van Sonderen E. Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. Int J Integr Care. 2002;2:e15.
37. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.